{
  "docId": "019de074-1cfe-7508-8ae3-4ba4db03f42e",
  "docSlug": "98d74dc525a4b13d13a1ee51c3af4583",
  "documentTitle": "Kymera | Results Presentation Deck | 63 slides",
  "authorId": "kymera",
  "authorName": "Kymera",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 62,
  "pageCount": 63,
  "prevPage": 61,
  "nextPage": 63,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-1cfe-7508-8ae3-4ba4db03f42e/62",
  "deckHref": "/decks/019de074-1cfe-7508-8ae3-4ba4db03f42e",
  "deckJsonHref": "/decks/019de074-1cfe-7508-8ae3-4ba4db03f42e.json",
  "deckAnchorHref": "/decks/019de074-1cfe-7508-8ae3-4ba4db03f42e#slide-62",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.32
      },
      "kind": "list",
      "text": "Kymera’s unique target selection strategy, using TPD to drug undrugged targets, has been validated, with initial demonstration of IRAK4 degradation providing a biologically and clinically differentiated/superior profile than SMI",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a119aaa8-9dbd-497d-898c-7360f8d2b399",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.9,
        "x": 0.05,
        "y": 0.5
      },
      "kind": "list",
      "text": "KT-474 data positions this mechanism and drug as a potential best in class oral drug in HS, AD and a broader variety of immune-inflammatory diseases with large market opportunity potential",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bf850d85-33e0-4962-a1f2-ea320675fb69",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.8
      },
      "kind": "list",
      "text": "In 2023 Kymera expects to share an expanded strategy to accelerate the path towards a disease agnostic global biotech",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c3a8c1a5-7d21-4b33-9a4e-4fb7b3d46eee",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.9,
        "x": 0.05,
        "y": 0.16
      },
      "kind": "list",
      "text": "Kymera platform and discovery engine have been validated across several programs in patients with cancer and inflammatory diseases, with fidelity of translation of PK, PD and safety",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d9202d68-0a8b-4849-bb86-5f0a59f5731b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.9,
        "x": 0.05,
        "y": 0.65
      },
      "kind": "list",
      "text": "The successful target selection strategy, molecular design, discovery and clinical execution and insights will allow acceleration and expansion of our pipeline in areas of high unmet need and large commercial opportunities",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eacc5d39-e901-47e8-aaa7-f714d566ed85",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.25,
        "x": 0.375,
        "y": 0.045
      },
      "kind": "title",
      "text": "Meeting Summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bad26a98-c3be-4d28-9999-b3999391bccd",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "7a944b99-d19c-41d4-8463-254ebe3ac979",
      "evidence": "list/bullet: Kymera’s unique target selection strategy, using TPD to drug undrugged targets, has been validated, with initial demonstration of IRAK4 degradation providing a biologically and clinically differentiated/supe",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 63,
      "from": 41,
      "beatId": "180a6b55-b123-4fd8-bfa4-ff2909acb6e8",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Action",
      "beatSlug": "aida-action",
      "evidence": "Conclusion, summary, and Q&A",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}